<?xml version="1.0" encoding="UTF-8"?>
<ref id="B12">
 <label>12.</label>
 <mixed-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Martinez-Hernandez</surname>
    <given-names>E</given-names>
   </name>
   <name>
    <surname>Guasp</surname>
    <given-names>M</given-names>
   </name>
   <name>
    <surname>Garcia-Serra</surname>
    <given-names>A</given-names>
   </name>
   <name>
    <surname>Maudes</surname>
    <given-names>E</given-names>
   </name>
   <name>
    <surname>Arino</surname>
    <given-names>H</given-names>
   </name>
   <name>
    <surname>Sepulveda</surname>
    <given-names>M</given-names>
   </name>
   <etal/>
  </person-group>. 
  <article-title>Clinical significance of anti-NMDAR concurrent with glial or neuronal surface antibodies</article-title>. 
  <source>Neurology.</source> (
  <year>2020</year>) 
  <volume>94</volume>:
  <fpage>e2302</fpage>â€“
  <lpage>10</lpage>. 
  <pub-id pub-id-type="doi">10.1212/WNL.0000000000009239</pub-id>
  <?supplied-pmid 32161029?>
  <pub-id pub-id-type="pmid">32161029</pub-id>
 </mixed-citation>
</ref>
